Cerus Corporation — Q1 2015 Form 10-Q Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction of blood components. The platelet and plasma systems were FDA-approved in December 2014 and were entering the U.S. commercial launch phase during the three months ended March 31, 2015. The red blood cell system remained in development.
The filing was signed May 8, 2015. Results are unaudited and not necessarily indicative of full-year performance.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Revenue | $7.7 million | $7.9 million | Down 2% |
| Gross profit | $3.0 million | $3.7 million | Down 20% |
| Gross margin | Approximately 39% | Approximately 47% | Down 8 percentage points |
| Operating loss | $(14.4) million | $(9.2) million | Loss increased 56% |
| Net loss | $(9.5) million | $(0.2) million | Loss increased substantially |
| Diluted loss per share | $(0.17) | $(0.12) | Worsened |
| Cash used in operating activities | $(15.8) million | $(9.8) million | Use increased |
Research and development expense increased 20% to $5.6 million, primarily for label-extension work and investigational device exemption studies. Selling, general and administrative expense increased 42% to $11.7 million due largely to U.S. launch preparation and expanded commercial capabilities.
The net loss included a $6.3 million non-cash gain from revaluation of the warrant liability, compared with a $9.0 million gain in the prior-year period. A $1.1 million foreign-exchange loss also affected results, compared with a small gain in Q1 2014.
Liquidity, capital resources and debt
- Cash and cash equivalents were $17.9 million at March 31, 2015, versus $22.8 million at December 31, 2014.
- Short-term investments increased to $94.0 million from $28.5 million, primarily reflecting investment of January offering proceeds.
- Total cash, cash equivalents and short-term investments were approximately $111.9 million.
- Working capital increased to $113.7 million from $45.7 million.
- Debt was approximately $9.9 million, consisting primarily of the Oxford Finance term loan; the debt matures in 2019 and bears interest at 6.95% for the drawn tranche.
- January 2015 equity financing generated approximately $75.4 million of net proceeds from the issuance of 14.6 million shares at $5.50 per share.
- Management stated that available liquidity, expected product-sales receipts and anticipated loan availability should fund requirements for at least the next twelve months, while acknowledging that the estimate depends on assumptions that may prove incorrect.
Material changes versus the prior comparable period
- Revenue declined modestly despite approximately 17% higher unit sales, primarily because the Euro weakened approximately 18% against the U.S. dollar.
- Gross margin declined because foreign-exchange effects increased the dollar cost of inventory purchased in Europe, in addition to product mix and volume effects.
- Operating expenses rose $4.4 million, driven by U.S. commercialization, clinical studies and development activities.
- Operating cash burn increased by $5.9 million, reflecting red blood cell and illuminator development, the U.S. launch and higher inventory investment.
- Financing liquidity improved materially following the January equity offering, although the share count and potential dilution increased.
- The warrant liability declined from $10.5 million to $4.2 million, producing a non-cash gain that materially reduced the reported net loss.
Guidance, outlook, commentary and risks
Management expected platelet and plasma revenue to increase as market acceptance expanded, including eventual U.S. contribution, but did not expect meaningful U.S. revenue during 2015. U.S. activity was focused on customer adoption and implementation.
Research and development and selling, general and administrative spending were expected to increase as Cerus expanded U.S. commercial operations, conducted post-approval and IDE studies, pursued label extensions and advanced the red blood cell program. Management did not expect red blood cell regulatory approvals for several years, if ever, and anticipated a CE Mark submission in the second half of 2016.
- Cerus relied substantially on Fresenius and other sole-source suppliers. Fresenius workforce reductions and any inability to continue manufacturing could impair product supply and customer demand.
- The business remained dependent on regulatory compliance, post-approval studies, customer licensing, reimbursement and adoption of a novel technology in the concentrated U.S. blood-collection market.
- The platelet system had labeling limitations in the United States, including restrictions relating to storage in 100% plasma and certain collection configurations.
- The company expected continuing losses and might require additional equity, debt or partnering capital. Additional equity financing could dilute shareholders.
- Access to the final $10 million loan tranche depended on achieving a specified trailing six-month revenue threshold; the filing did not provide the threshold amount.
- Foreign-exchange volatility, particularly involving the Euro and Russian Ruble, could adversely affect revenue and margins.
- The company disclosed material weaknesses in internal control over financial reporting relating to inventory valuation, cost of product revenue and the timeliness and accuracy of accrued-liability adjustments. Disclosure controls were therefore not effective as of March 31, 2015.
- Contractual obligations totaled approximately $24.1 million, including $9.3 million of minimum purchase commitments, $12.5 million of debt payments including interest, and $1.6 million of operating leases.
Most important facts for investors to verify
- Whether U.S. adoption of the FDA-approved platelet and plasma systems accelerates sufficiently to offset continuing operating losses and cash burn.
- Whether gross margins recover from the approximately 39% Q1 level as foreign-exchange effects, production volumes and product mix change.
- Whether Cerus achieves the revenue condition required to access the final $10 million Oxford Finance tranche.
- Whether the company remediates the disclosed material weaknesses and establishes effective internal controls.
- Whether Fresenius and other sole-source suppliers can maintain adequate, compliant and timely product supply.
- Whether the required post-approval, IDE and red blood cell clinical programs meet regulatory and commercial objectives without materially increasing funding needs.
- The accounting and valuation impact of Cerus’s 396,700-share investment in Aduro Biotech following Aduro’s April 2015 IPO; the investment was carried at zero at March 31, 2015.